Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Summary: Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thu...

Full description

Bibliographic Details
Main Authors: Matthew J. Gorman, Nita Patel, Mimi Guebre-Xabier, Alex L. Zhu, Caroline Atyeo, Krista M. Pullen, Carolin Loos, Yenny Goez-Gazi, Ricardo Carrion, Jr., Jing-Hui Tian, Dansu Yuan, Kathryn A. Bowman, Bin Zhou, Sonia Maciejewski, Marisa E. McGrath, James Logue, Matthew B. Frieman, David Montefiori, Colin Mann, Sharon Schendel, Fatima Amanat, Florian Krammer, Erica Ollmann Saphire, Douglas A. Lauffenburger, Ann M. Greene, Alyse D. Portnoff, Michael J. Massare, Larry Ellingsworth, Gregory Glenn, Gale Smith, Galit Alter
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Cell Reports Medicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666379121002639